AVANIR Pharmaceuticals to Announce First Fiscal Quarter 2002 Results On February 7

SAN DIEGO, Feb 5, 2002 /PRNewswire-FirstCall via COMTEX/ -- AVANIR Pharmaceuticals (Amex: AVN) will announce financial results for the first fiscal quarter ended December 31, 2001 after the market closes on Thursday, February 7, 2002.

Following the release, management will host a conference call with a simultaneous webcast at 1:30 p.m. Pacific/ 4:30 p.m. Eastern to discuss first fiscal quarter 2002 operating performance and outlook. The webcast will feature President and Chief Executive Officer Gerald J. Yakatan, Ph.D., Vice President and Chief Financial Officer Gregory Hanson and Xenerex Biosciences President and Chief Operating Officer J. David Hansen, and will be available live via the Internet by accessing AVANIR's web site at www.avanir.com . Individual investors can also listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network such as America Online's Personal Finance Channel (available to AOL subscribers), Fidelity Investments(R) ( Fidelity.com ) and others. Institutional investors can access the call via CCBN's password protected event management site, StreetEvents ( www.streetevents.com ).

For those who cannot listen to the live broadcast, the online replays will be available for 90 days, or a phone replay will be available through February 14, 2002, by dialing 888-266-2086 or 703-925-2435 and entering the passcode 5824309.

AVANIR Pharmaceuticals, based in San Diego, is a diversified biopharmaceutical company with an FDA-approved drug currently on the market. AVANIR is engaged in research, development, commercialization, licensing and sales of innovative drug products and antibody generation services. The Company's website is www.avanir.com .

AVANIR press releases, including any forward-looking statements contained therein, should be reviewed in conjunction with the company's Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." Research findings are not always supportable by evidence obtained from subsequent clinical trials. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

SOURCE AVANIR Pharmaceuticals

CONTACT:
General Information, Kristen McNally,
+1-310-407-6548, kmcnally@webershandwick.com,
Analyst/Investor, Tricia Ross, +1-310-407-6540,
tross@webershandwick.com,
or Media, Al Orendorff,
+1-312-640-6775, aorendorff@webershandwick.com,
all of FRB|Weber Shandwick for AVANIR Pharmaceuticals;

or Investor Relations, Patrice Saxon of AVANIR Pharmaceuticals,
+1-858-622-5202, psaxon@avanir.com

URL: http://www.avanir.com
http://www.prnewswire.com

Copyright (C) 2002 PR Newswire. All rights reserved.